{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T20:54:48Z","timestamp":1785704088906,"version":"3.56.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck & Co Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.clml.2026.05.008","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T15:18:39Z","timestamp":1779376719000},"page":"e996-e1004","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prospective Study of Cytomegalovirus Reactivation in Patients With Multiple Myeloma Receiving Anti-CD38 and BCMA Therapies"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8994-2023","authenticated-orcid":false,"given":"Emily","family":"Baneman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9770-886X","authenticated-orcid":false,"given":"Samantha E.","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meenakshi","family":"Rana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larysa","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1862-7867","authenticated-orcid":false,"given":"Hulya","family":"Kocyigit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Moshier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.clml.2026.05.008_bib0001","first-page":"7","article-title":"Cancer statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"7","key":"10.1016\/j.clml.2026.05.008_bib0002","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.clml.2021.02.002","article-title":"Epidemiology and risks of infections in patients with multiple myeloma managed with newer generation therapies","volume":"21","author":"Lim","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2026.05.008_bib0003","unstructured":"U.S. Food & Drug Administration. Oncology (cancer)\/hematologic malignancies approval notifications. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/oncology-cancerhematologic-malignancies-approval-notifications. Accessed November 2, 2025."},{"issue":"1","key":"10.1016\/j.clml.2026.05.008_bib0004","doi-asserted-by":"crossref","DOI":"10.1080\/16078454.2024.2448898","article-title":"Risk of infections in bispecific antibody therapy for multiple myeloma: a comprehensive review of literature","volume":"30","author":"Alshammari","year":"2025","journal-title":"Hematology"},{"issue":"8","key":"10.1016\/j.clml.2026.05.008_bib0005","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1086\/605664","article-title":"Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents","volume":"49","author":"Nucci","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clml.2026.05.008_bib0006","article-title":"Cytomegalovirus reactivation after bortezomib treatment for multiple myeloma and light chain amyloidosis","author":"Sharpley","year":"2019","journal-title":"Eur J Haematol"},{"issue":"1","key":"10.1016\/j.clml.2026.05.008_bib0007","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/ejh.12551","article-title":"Cytomegalovirus reactivation in patients with multiple myeloma","volume":"96","author":"Hasegawa","year":"2016","journal-title":"Eur J Haematol"},{"issue":"11","key":"10.1016\/j.clml.2026.05.008_bib0008","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1016\/j.bbmt.2012.06.008","article-title":"Cytomegalovirus reactivation following autologous peripheral blood stem cell transplantation for multiple myeloma in the era of novel chemotherapeutics and tandem transplantation","volume":"18","author":"Kim","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2026.05.008_bib0009","doi-asserted-by":"crossref","DOI":"10.1111\/tid.12162","article-title":"High incidence of post-transplant cytomegalovirus reactivations in myeloma patients undergoing autologous stem cell transplantation after treatment with bortezomib-based regimens: a survey from the Rome Transplant Network","author":"Marchesi","year":"2014","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.clml.2026.05.008_bib0010","doi-asserted-by":"crossref","DOI":"10.1111\/tid.12309","article-title":"Evaluation of risk of symptomatic cytomegalovirus reactivation in myeloma patients treated with tandem autologous stem cell transplantation and novel agents: a single-institution study","author":"Marchesi","year":"2014","journal-title":"Transpl Infect Dis"},{"issue":"4","key":"10.1016\/j.clml.2026.05.008_bib0011","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1080\/10428194.2023.2172982","article-title":"Cytomegalovirus and Epstein-Barr virus infection during daratumumab treatment in patients with multiple myeloma","volume":"64","author":"Li","year":"2023","journal-title":"Leuk Lymphoma"},{"issue":"14","key":"10.1016\/j.clml.2026.05.008_bib0012","article-title":"Cytomegalovirus reactivation is frequent in multiple myeloma patients treated with daratumumab-based regimens","volume":"13","author":"De Novellis","year":"2024","journal-title":"Cancer Med"},{"issue":"8","key":"10.1016\/j.clml.2026.05.008_bib0013","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.clml.2024.03.012","article-title":"Clinical significance of cytomegalovirus reactivation in patients with plasma cell dyscrasia who were treated with anti-CD38 monoclonal antibody: a retrospective analysis in a single institution","volume":"24","author":"Matsunaga","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"10.1016\/j.clml.2026.05.008_bib0014","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s12185-024-03770-8","article-title":"Cytomegalovirus infection during daratumumab therapy in patients with newly diagnosed multiple myeloma","volume":"120","author":"Kikuchi","year":"2024","journal-title":"Int J Hematol"},{"issue":"4","key":"10.1016\/j.clml.2026.05.008_bib0015","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1093\/cid\/ciad708","article-title":"Cytomegalovirus (CMV) reactivation and CMV-specific cell-mediated immunity after chimeric antigen receptor T-cell therapy","volume":"78","author":"Kampouri","year":"2024","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.clml.2026.05.008_bib0016","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines13010036","article-title":"Outcomes of Idecabtagene Vicleucel therapy in patients with relapsed\/refractory multiple myeloma: a single-institution experience","volume":"13","author":"Trando","year":"2025","journal-title":"Biomedicines"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2026.05.008_bib0017","doi-asserted-by":"crossref","first-page":"7198","DOI":"10.1182\/blood-2022-163757","article-title":"Timing and nature of infections in multiple myeloma patients treated with anti-BCMA CAR-T cells","volume":"140","author":"Lancman","year":"2022","journal-title":"Blood"},{"issue":"79","key":"10.1016\/j.clml.2026.05.008_bib0018","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1093\/cid\/ciae053","article-title":"The clinical significance of Cytomegalovirus viremia after chimeric antigen receptor T-cell therapy","author":"Hammond","year":"2024","journal-title":"Clin Infect Dis"},{"issue":"10","key":"10.1016\/j.clml.2026.05.008_bib0019","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.jtct.2024.07.018","article-title":"Best practice considerations by The American Society of Transplant and Cellular Therapy: infection prevention and management after chimeric antigen receptor T cell Therapy for hematological malignancies","volume":"30","author":"Shahid","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"6","key":"10.1016\/j.clml.2026.05.008_bib0020","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1002\/cncr.35107","article-title":"Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed\/refractory multiple myeloma in the MajesTEC-1 study","volume":"130","author":"Nooka","year":"2024","journal-title":"Cancer"},{"issue":"13","key":"10.1016\/j.clml.2026.05.008_bib0021","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1182\/bloodadvances.2022009435","article-title":"Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis","volume":"7","author":"Mazahreh","year":"2023","journal-title":"Blood Adv"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2026.05.008_bib0022","doi-asserted-by":"crossref","first-page":"10073","DOI":"10.1182\/blood-2022-163733","article-title":"Infections and severe hypogammaglobulinemia in multiple myeloma patients treated with anti-BCMA bispecific antibodies","volume":"140","author":"Lancman","year":"2022","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2026.05.008_bib0023","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-023-00808-8","article-title":"Infectious complications of bispecific antibody therapy in patients with multiple myeloma","volume":"13","author":"Sim","year":"2023","journal-title":"Blood Cancer J"},{"issue":"Supplement 2","key":"10.1016\/j.clml.2026.05.008_bib0024","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/S2152-2650(25)03492-5","article-title":"Monitoring and management of CMV and other viral reactivations with bispecific antibodies (BsAbs) for patients with relapsed and refractory multiple myeloma (RRMM)","volume":"25","author":"Feast","year":"2025","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"9","key":"10.1016\/j.clml.2026.05.008_bib0025","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1093\/cid\/ciy295","article-title":"Absolute lymphocyte count: a predictor of recurrent cytomegalovirus disease in solid organ transplant recipients","volume":"67","author":"Gardiner","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"10","key":"10.1016\/j.clml.2026.05.008_bib0026","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofy230","article-title":"Absolute lymphocyte count thresholds: a simple, readily available tool to predict the risk of cytomegalovirus infection after transplantation","volume":"5","author":"Meesing","year":"2018","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"10.1016\/j.clml.2026.05.008_bib0027","first-page":"163","article-title":"Risk of infections in multiple myeloma. A population-based study on 8,672 multiple myeloma patients diagnosed 2008-2021 from the Swedish Myeloma Registry","volume":"110","author":"Blimark","year":"2025","journal-title":"Haematologica"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026001515?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026001515?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T20:19:51Z","timestamp":1785701991000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265026001515"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":27,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2152265026001515"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2026.05.008","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prospective Study of Cytomegalovirus Reactivation in Patients With Multiple Myeloma Receiving Anti-CD38 and BCMA Therapies","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2026.05.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}